title: Cell therapy for cerebral hemorrhage: Five year follow-up report.
abstract: The aim of the study was to examine treatment of cerebral hemorrhages with bone-marrow or human umbilical cord-derived mesenchymal stem cells (BMSCs or Hu-MSCs) and conventional surgical approaches, and determine and compare the effectiveness, feasibility, safety and reproducibility of each method. A retrospective analysis was performed on a cohort of cell-treated cerebral hemorrhage patients from October 1, 2007 to October 1, 2009. A total of 24 patients, all of whom received conventional surgical treatment, were classified as follows: i) The control group consisted of 8 patients who received only hematoma removal surgery, ii) the autologous group consisted of 7 patients who received additional autologous bone marrow mononuclear cell transplantation, and iii) the allograft group consisted of 9 patients who received additional umbilical cord mononuclear cell transplantation. After conventional hematoma removal surgery and X-ray supervision within 24 h and at 7 days, neurological disability and function tests were completed 3, 6, 12, 36 and 60 months later. The T-cell marker plasma levels were analyzed after 60 months. The results showed that, at approximately 3.5 months after graft the hematomas in all the groups were completely reabsorbed as observed on computed tomography scans. However, the functional outcomes in the cell-transplanted groups were better than in the control group after 5 years. While the National Institutes of Health Stroke Scale, modified Rankin score and modified Barthel index scores were simliar in the cell-transplanted groups, patients in the allograft group had better outcomes than those in the autologous graft group starting at 3 months and until the end of the follow-up period. The serum levels of T-cell markers CD4, CD56 and human leukocyte antigen-DR in the allograft group showed no signs of immunogenic graft complications and there were no significant differences in T-cell subtypes among the patient groups. The results of the present study suggest that, treatment of cerebral hemorrhage patients can be safely and effectively accomplished using Hu-MSC grafting and larger clinical trials should be considered in the future.
authors.affiliation: Department of Neurosurgery, Siping Hospital of China Medical University, Siping, Jilin 136000, P.R. China; Tuhua Bioengineering Company Ltd., Siping, Jilin 136000, P.R. China.
authors.forename: Zhitian
authors.initials: Z
authors.lastname: Chang
authors.affiliation: Department of Neurovascular Surgery, General Hospital of Armed Police Forces, Beijing 100000, P.R. China.
authors.forename: Gengsheng
authors.initials: G
authors.lastname: Mao
authors.affiliation: Department of Neurobiology of North China University, Jilin 132013, P.R. China.
authors.forename: Lizhong
authors.initials: L
authors.lastname: Sun
authors.affiliation: Department of Tissue Engineering, China Medical University, Shenyang, Liaoning 110122, P.R. China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Ao
authors.affiliation: Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China.
authors.forename: Yongquan
authors.initials: Y
authors.lastname: Gu
authors.affiliation: Tuhua Bioengineering Company Ltd., Siping, Jilin 136000, P.R. China; The Key Tissue Engineering Laboratory of Jilin Province, Jilin 136000, P.R. China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
keywords: CD4; CD56; CD8; cerebral hemorrhage; human leukocyte antigen-DR; human umbilical cord-derived mesenchymal stem cells